Heidi Ko: Manuscript on immune characterization of HER2-low vs. HER-zero breast cancer
Heidi Ko, Medical Director, Medical Affairs at shared a post on LinkedIn:
“Our manuscript on immune characterization of HER2-low vs. HER-zero breast cancer is published.
Some highlights of our findings:
There were no significant differences in immune-related gene expressions such as PD-L1, TIM-3, LAG-3, and TIGIT between HER2-low and HER2-zero breast cancer
HER2-low breast cancers were associated with a higher proportion of ER-positivity.
Patients with HER2-low breast cancer have a longer median OS than those with HER2-zero cancer, suggesting that there is a prognostic difference between the two, primarily driven by ER expression.
Congratulations to our team.
I’m grateful for everyone’s support and dedication to help fulfill this breast oncologist’s dream of understanding and writing about the genomic and immune phenotypes of HER2-low breast cancer ”
Source: Heidi Ko/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023